CONNECTING BREAKTHROUGH IDEAS WITH GROUNDBREAKING RESULTS

CONNECTING BREAKTHROUGH IDEAS WITH GROUNDBREAKING RESULTS

Marc Kozin – Director Nominee

Marc Kozin serves as a member of our Board of Directors. Mr. Kozin is a professional Board Member, having served on over a dozen Boards in a variety of roles and on all committees. He has experience as Chair, Vice Chair, Lead Independent Director and Committee Chairs.

Previously, Mr. Kozin was a career strategy consultant, having served as President of L.E.K. Consulting’s North American practice from 1997 to 2012. He began his career at L.E.K. in 1987 by helping establish the Boston office. He has over 35 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management. He also led the development of L.E.K.’s industry leading life science strategic planning practice.

Mr. Kozin currently sits on several Boards. He has served as a director of UFP Technologies (NASDAQ: UFPT) since 2006 where he is lead director. In November, 2020, he joined the Board of Vascular Biogenics (NASDAQ: VBLT) as Vice Chairman. In January 2019, he joined the Board of Dicerna Pharmaceuticals (NASDAQ: DRNA). In January 2013, he joined the Strategy Advisory Board of HealthCare Royalty Partners where he is Chairman. On the non-profit side, he serves on the Board of The Greenlight Fund.

Since becoming a professional Board member, Mr. Kozin has also served on the Boards of several companies since sold, including Endocyte (NASDAQ: ECYT), a small molecule targeted therapeutic company sold to Novartis, Dyax (NASDAQ: DYAX), an integrated biotechnology company sold to Shire, OvaScience (NASDAQ: OVAS), a fertility company merged with Millendo Therapeutics and Flex Pharmaceuticals (NASDAQ: FLKS) merged with Salarius Pharmaceuticals. Mr. Kozin has also served on the boards of directors of Frequency Therapeutics, Brandwise, Inc., Lynx Therapeutics, Inc., Assurance Medical, Inc., Medical Simulation Corporation, Advizex, and CrunchTime! Information Systems. Mr. Kozin was also on the Board of Governors at New England Medical Center and the Board of DukeEngage.

Mr. Kozin received his B.A. with Distinction, Magna Cum Laude, in Economics from Duke University in 1983. He was awarded an M.B.A. with Distinction from The Wharton School, University of Pennsylvania in 1987. We believe Mr. Kozin will be well qualified to serve as a member of our Board of Directors due to his extensive experience in both health care and transactions.

Marc Kozin – Director Nominee

Marc Kozin serves as a member of our Board of Directors. Mr. Kozin is a professional Board Member, having served on over a dozen Boards in a variety of roles and on all committees. He has experience as Chair, Vice Chair, Lead Independent Director and Committee Chairs.

Previously, Mr. Kozin was a career strategy consultant, having served as President of L.E.K. Consulting’s North American practice from 1997 to 2012. He began his career at L.E.K. in 1987 by helping establish the Boston office. He has over 35 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management. He also led the development of L.E.K.’s industry leading life science strategic planning practice.

Mr. Kozin currently sits on several Boards. He has served as a director of UFP Technologies (NASDAQ: UFPT) since 2006 where he is lead director. In November, 2020, he joined the Board of Vascular Biogenics (NASDAQ: VBLT) as Vice Chairman. In January 2019, he joined the Board of Dicerna Pharmaceuticals (NASDAQ: DRNA). In January 2013, he joined the Strategy Advisory Board of HealthCare Royalty Partners where he is Chairman. On the non-profit side, he serves on the Board of The Greenlight Fund.

Since becoming a professional Board member, Mr. Kozin has also served on the Boards of several companies since sold, including Endocyte (NASDAQ: ECYT), a small molecule targeted therapeutic company sold to Novartis, Dyax (NASDAQ: DYAX), an integrated biotechnology company sold to Shire, OvaScience (NASDAQ: OVAS), a fertility company merged with Millendo Therapeutics and Flex Pharmaceuticals (NASDAQ: FLKS) merged with Salarius Pharmaceuticals. Mr. Kozin has also served on the boards of directors of Frequency Therapeutics, Brandwise, Inc., Lynx Therapeutics, Inc., Assurance Medical, Inc., Medical Simulation Corporation, Advizex, and CrunchTime! Information Systems. Mr. Kozin was also on the Board of Governors at New England Medical Center and the Board of DukeEngage.

Mr. Kozin received his B.A. with Distinction, Magna Cum Laude, in Economics from Duke University in 1983. He was awarded an M.B.A. with Distinction from The Wharton School, University of Pennsylvania in 1987. We believe Mr. Kozin will be well qualified to serve as a member of our Board of Directors due to his extensive experience in both health care and transactions.

Isleworth Healthcare Acquisition Corporation
970 Lake Carillon Drive
Feather Sound, Suite 300
St. Petersburg, Florida 33716
(727) 245-0146.